About Virchow Biotech
Virchow Biotech is a Healthcare company based in Hyderabad (India) founded in 2000. Recombinant biologicals for wound care and bone disorders are developed. The company has 1,048 employees. Its chief executive, as recorded, is Ravi Kumar Gattupalli. Its Indian entity Virchow Biotech Private Limited reported revenue of ₹758 Cr. Virchow Biotech offers products and services including SCARAZE, CADEXOMER IODINE, LEUPROLIDE ACETATE, ULINASTATIN, and Bifidobacterium bifidum. Its focus areas include Diversified Pharmaceuticals.
Company details
Virchow Biotech is focussed developing biologicals and biogeneric products. It is focussed on the development of products based on recombinant DNA and molecular biology. It developed two bio-generic human therapeutics, Healace (rh PDGF-BB, marketed in India as Plermin by Dr. Reddys) and Osteotide (marketed in India as Bonista by Ranbaxy). Its product portfolio consists of 15 bio-generic products covering wound care and haemostasis, ophthalmology, orthopedics, probiotics and gastroenterology. It also has five other recombinant bio-generics in the pipeline. It is filing for US FDA approval for its developed advanced wound care products and has received Drug controls (DCGI) approval for conducting clinical trials on periogen, a recombinant therapeutic product for periodontal diseases.
- Headquarters Hyderabad, India
- Employees 1,048
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website virchowbiotech.com
- Legal Name Virchow Biotech Private Limited
- Date of Incorporation 04 Apr, 2001
- Jurisdiction \Hyderabad, Telangana, India
- Annual Revenue₹758 Cr
FY 2025 · +5% YoY
- Net Profit₹77.65 Cr
FY 2025 · 10% margin
- EBITDA₹136 Cr
FY 2025 · 18% margin
- Employee Count1,048
Associated legal entities of Virchow Biotech
Virchow Biotech operates through Virchow Biotech Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Virchow Biotech Private Limited CIN U24210TG2001PTC036520 | Active | 04 Apr 2001 | Hyderabad, Telangana | ₹758 Cr | 1,048 | 4 | View details |
Products & Services of Virchow Biotech
Virchow Biotech offers a comprehensive portfolio of products and services, including SCARAZE, CADEXOMER IODINE, LEUPROLIDE ACETATE, ULINASTATIN, and Bifidobacterium bifidum.
Product for wound healing and scar reduction.
Antiseptic for wound care applications.
Hormone treatment for gynecological conditions.
Protease inhibitor for urological treatments.
Probiotic strain for digestive health support.
Board of directors of Virchow Biotech Private Limited (Virchow Biotech)
Virchow Biotech Private Limited is the primary company behind Virchow Biotech. The board of Virchow Biotech Private Limited currently have 4 directors; the longest-serving is Hemanth Nandigala, appointed in 2001. 7 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Hemanth Nandigala DIN 01561731 | Managing Director | 04 Apr 2001 | 25 yrs 7 mo | Virchow Biotech Private Limited |
| Tummuru Murali Krishna Reddy DIN 02469013 | Managing Director | 22 Nov 2001 | 24 yrs 11 mo | Virchow Biotech Private Limited |
| Prasanth Nandigala DIN 01740471 | Director | 04 Jan 2024 | 2 yrs 10 mo | Virchow Biotech Private Limited |
| Mundla Maha Vishnu DIN 02470664 | Director | 04 Jan 2024 | 2 yrs 10 mo | Virchow Biotech Private Limited |
People of Virchow Biotech
3 people are tracked at Virchow Biotech (1 in leadership, 2 in team); the tracked headcount is 1,048.
| Name | Role | Group |
|---|---|---|
Ravi Kumar Gattupalli | CEO | Leadership |
Amol Tungenwar | Senior Executive | Team |
Vamsi Krishna Ravula | Senior Research Associate | Team |
Complete people profiles for Virchow Biotech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Virchow Biotech
Figures of Virchow Biotech Private Limited, the primary company behind Virchow Biotech, for FY 2025. Revenue was ₹758 Cr (+5% year on year). Net profit was ₹77.65 Cr (10% margin). EBITDA was ₹136 Cr (18% margin). Revenue has grown at a compounded annual rate of +10% over three years and +17% over five years.
- ₹758 CrRevenue · FY 2025 · +5% YoY
- ₹77.65 CrNet profit · 10% margin
- ₹136 CrEBITDA · 18% margin
- ₹17.03 CrPaid-up capital
- 1,048Employees (provident fund records)
- +10%Revenue CAGR, 3 years
- +17%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Virchow Biotech Private Limited are on its company page.
Detailed financial statements for Virchow Biotech
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of Virchow Biotech
The website of Virchow Biotech (virchowbiotech.com) receives about 1.4K visits a month and ranks #4,149,585 among all websites worldwide, #5,156 in Biotechnology and Pharmaceuticals.
- Monthly visits1.4K
▼ 55.9% vs previous month
- Unique visitors1.4K
per month
- Global rank#4,149,585
among all websites
- Category rank#5,156
Health · Biotechnology and Pharmaceuticals
- Bounce rate25%
- Pages per visit3.3
- Average visit2 min 40 sec
- DevicesDesktop 31% · Mobile 69%
Websites whose visitors overlap most with Virchow Biotech. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| concordbiotech.com | 100% | 3.7K | #4,215,278 | View details | |
signalsmag.com | signalsmag.com | 100% | – | ||
biotech-register.com | biotech-register.com | 100% | – | ||
| fiercebiotech.com | 81% | 858.3K | #81,022 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Virchow Biotech
Complete news archive for Virchow Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Virchow Biotech
Virchow Biotech was founded in 2000.
Virchow Biotech is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Ravi Kumar Gattupalli is the CEO of Virchow Biotech, as recorded in our data.
Virchow Biotech has 1,048 employees.
The primary company behind Virchow Biotech, Virchow Biotech Private Limited, reported revenue of ₹758 Cr for FY 2025, up 5% year on year.
Virchow Biotech is focussed developing biologicals and biogeneric products. It is focussed on the development of products based on recombinant DNA and molecular biology. It developed two bio-generic human therapeutics, Healace (rh PDGF-BB, marketed in India as Plermin by Dr. Reddys) and Osteotide (marketed in India as Bonista by Ranbaxy). Its product portfolio consists of 15 bio-generic products covering wound care and haemostasis, ophthalmology, orthopedics, probiotics and gastroenterology. It also has five other recombinant bio-generics in the pipeline. It is filing for US FDA approval for its developed advanced wound care products and has received Drug controls (DCGI) approval for conducting clinical trials on periogen, a recombinant therapeutic product for periodontal diseases.
Virchow Biotech offers SCARAZE, CADEXOMER IODINE, LEUPROLIDE ACETATE, ULINASTATIN, and Bifidobacterium bifidum.
Virchow Biotech operates through Virchow Biotech Private Limited.
The legal entities of Virchow Biotech currently have 4 directors, including Tummuru Murali Krishna Reddy, Prasanth Nandigala, Mundla Maha Vishnu and others.